Medical News Today -- LGC, the international science-based company and market leader in analytical, forensic and diagnostic services and reference standards, is applying its HyBeacons® genotyping technology to Europe’s first-ever large scale trial of pharmacogenetic-guided anticoagulation therapy. LGC is pleased to announce that the first patient within the trial has been successfully genotyped and treatment has commenced.
